Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Change in Receivables (2020 - 2023)

Barinthus Biotherapeutics' Change in Receivables history spans 4 years, with the latest figure at -$194000.0 for Q3 2023.

  • For Q3 2023, Change in Receivables rose 98.21% year-over-year to -$194000.0; the TTM value through Jun 2024 reached -$194000.0, up 98.85%, while the annual FY2023 figure was -$5.8 million, 199.43% down from the prior year.
  • Change in Receivables reached -$194000.0 in Q3 2023 per BRNS's latest filing, up from -$645000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $18.4 million in Q1 2022 to a low of -$10.9 million in Q3 2022.
  • Average Change in Receivables over 4 years is -$67000.0, with a median of -$284000.0 recorded in 2021.
  • The largest YoY upside for Change in Receivables was 8923.08% in 2022 against a maximum downside of 181200.0% in 2022.
  • A 4-year view of Change in Receivables shows it stood at $448000.0 in 2020, then crashed by 116.29% to -$73000.0 in 2021, then crashed by 350.68% to -$329000.0 in 2022, then soared by 41.03% to -$194000.0 in 2023.
  • Per Business Quant, the three most recent readings for BRNS's Change in Receivables are -$194000.0 (Q3 2023), -$645000.0 (Q2 2023), and -$5.0 million (Q1 2023).